These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2783457

  • 1. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
    Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A.
    J Nucl Med; 1989 Jan; 30(1):88-92. PubMed ID: 2783457
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D-2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N- [(1-ethyl-2-pyrrolidinyl)methyl]benzamide.
    Kung HF, Kasliwal R, Pan SG, Kung MP, Mach RH, Guo YZ.
    J Med Chem; 1988 May; 31(5):1039-43. PubMed ID: 2966245
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo D2-dopamine receptor binding with [123I]S(-) iodobenzamide ([123I]IBZM) in rat and human brain.
    Verhoeff NP, Bobeldijk M, Feenstra MG, Boer GJ, Maas MA, Erdtsieck-Ernste E, de Bruin K, van Royen EA.
    Int J Rad Appl Instrum B; 1991 May; 18(8):837-46. PubMed ID: 1839302
    [Abstract] [Full Text] [Related]

  • 4. In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): a potential imaging ligand for D-2 dopamine receptors in SPECT.
    Brücke T, Tsai YF, McLellan C, Singhanyom W, Kung HF, Cohen RM, Chiueh CC.
    Life Sci; 1988 May; 42(21):2097-104. PubMed ID: 3260318
    [Abstract] [Full Text] [Related]

  • 5. The characterization of IBF as a new selective dopamine D-2 receptor imaging agent.
    Kung MP, Kung HF, Billings J, Yang Y, Murphy RA, Alavi A.
    J Nucl Med; 1990 May; 31(5):648-54. PubMed ID: 2140409
    [Abstract] [Full Text] [Related]

  • 6. Preparation and biodistribution of [125I]IBZM: a potential CNS D-2 dopamine receptor imaging agent.
    Kung HF, Guo YZ, Billings J, Xu X, Mach RH, Blau M, Ackerhalt RE.
    Int J Rad Appl Instrum B; 1988 May; 15(2):195-201. PubMed ID: 2966782
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
    Murphy RA, Kung HF, Kung MP, Billings J.
    J Med Chem; 1990 Jan; 33(1):171-8. PubMed ID: 2136916
    [Abstract] [Full Text] [Related]

  • 8. Comparison of in vivo D-2 dopamine receptor binding of IBZM and NMSP in rat brain.
    Kung HF, Billings JJ, Guo YZ, Mach RH.
    Int J Rad Appl Instrum B; 1988 Jan; 15(2):203-8. PubMed ID: 2966783
    [Abstract] [Full Text] [Related]

  • 9. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Velchik MG, Billings J, Pan S, Noto R, Rausch.
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [Abstract] [Full Text] [Related]

  • 10. Characterization of radioiodinated TISCH: a high-affinity and selective ligand for mapping CNS D1 dopamine receptor.
    Billings JJ, Kung MP, Chumpradit S, Mozley D, Alavi A, Kung HF.
    J Neurochem; 1992 Jan; 58(1):227-36. PubMed ID: 1530770
    [Abstract] [Full Text] [Related]

  • 11. Amphetamine-stimulated dopamine release competes in vivo for [123I]IBZM binding to the D2 receptor in nonhuman primates.
    Innis RB, Malison RT, al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, Zoghbi SS, Baldwin RM, Laruelle M, Smith EO.
    Synapse; 1992 Mar; 10(3):177-84. PubMed ID: 1532675
    [Abstract] [Full Text] [Related]

  • 12. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 13. [In vivo characteristics of IBZM in rat brains: an agent for quantitative SPECT imaging of dopamine D2 receptors. Preparation of 125I-IBZM and its biodistribution and kinetic properties].
    Matsumura K, Toyama H, Nakashima H, Ichise M, Kurami M, Nakagawa T, Maeda H, Takeuchi A, Koga S.
    Kaku Igaku; 1994 May; 31(5):513-9. PubMed ID: 8028224
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo characterization of R(+)-FIDA2: a dopamine D2-like imaging agent.
    Vessotskie JM, Kung MP, Chumpradit S, Romaniello G, McElgin W, Frederick D, Malison RT, Kung HF.
    J Nucl Med; 1995 Jul; 36(7):1282-8. PubMed ID: 7790957
    [Abstract] [Full Text] [Related]

  • 15. [Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
    Bettin S, Kämpfer I, Seese A, Schäfer A, Reuter M, Lössner J, Dietrich J, Wagner A, Knapp WH.
    Nuklearmedizin; 1997 Aug; 36(5):167-72. PubMed ID: 9380528
    [Abstract] [Full Text] [Related]

  • 16. In vivo measurement of haloperidol affinity to dopamine D2/D3 receptors by [123I]IBZM and single photon emission computed tomography.
    Videbaek C, Toska K, Friberg L, Holm S, Angelo HR, Knudsen GM.
    J Cereb Blood Flow Metab; 2001 Jan; 21(1):92-7. PubMed ID: 11149673
    [Abstract] [Full Text] [Related]

  • 17. NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.
    Hall H, Högberg T, Halldin C, Köhler C, Ström P, Ross SB, Larsson SA, Farde L.
    Psychopharmacology (Berl); 1991 Jan; 103(1):6-18. PubMed ID: 1672460
    [Abstract] [Full Text] [Related]

  • 18. Characterization of membrane-bound and soluble D2 receptors in canine caudate using [125I]IBZM.
    Schonwetter BS, Luedtke RR, Kung MP, Billings J, Kung HF, Molinoff PB.
    J Pharmacol Exp Ther; 1989 Jul; 250(1):110-6. PubMed ID: 2526213
    [Abstract] [Full Text] [Related]

  • 19. Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging.
    Leslie WD, Abrams DN, Greenberg CR, Hobson D.
    J Nucl Med; 1996 Oct; 37(10):1589-91. PubMed ID: 8862288
    [Abstract] [Full Text] [Related]

  • 20. Comparison of in vivo dopamine D2 receptor binding of [(123)I]AIBZM and [(123)I]IBZM in rat brain.
    Li H, Gildehaus FJ, Dresel S, Patt JT, Shen M, Zhu T, Liu B, Tang Z, Tatsch K, Hahn K.
    Nucl Med Biol; 2001 May; 28(4):383-9. PubMed ID: 11395310
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.